Windtree Therapeutics
WINT
WINT was delisted on the 20th of August, 2025.
15 hedge funds and large institutions have $279K invested in Windtree Therapeutics in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
36% more funds holding
Funds holding: 11 → 15 (+4)
0% less ownership
Funds ownership: 0% → 0% (-0%)
46% less capital invested
Capital invested by funds: $521K → $279K (-$242K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$26.7K |
| 2 |
Millennium Management
New York
|
+$17.8K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$8.89K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$8.89K |
| 5 |
HF
HRT Financial
New York
|
+$8.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$53.3K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$8.89K |
| 3 |
VF
Virtu Financial
New York
|
-$8.89K |
| 4 |
DM
Deerfield Management
New York
|
-$6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5K |
WINT Hedge Fund Activity: Q4 2022 in Review
15 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q4 2022, worth a combined $279K — down 46% from $521K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new WINT positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Envestnet Asset Management, adding an estimated $26.7K. The largest seller was Vanguard Group, cutting an estimated $53.3K.
- 15 institutional investors held Windtree Therapeutics (WINT) as of Q4 2022, up from 11 in Q3 2022.
- Funds reported $279K of Windtree Therapeutics stock for Q4 2022, down 46% quarter-over-quarter.
- 5 funds opened new Windtree Therapeutics positions in Q4 2022 and 1 closed out, a net change of +4 holders.
- The largest Windtree Therapeutics buyer in Q4 2022 was Envestnet Asset Management, an estimated $26.7K added.
- The largest Windtree Therapeutics seller in Q4 2022 was Vanguard Group, an estimated $53.3K sold.
Based on aggregated 13F filings for Q4 2022.